RenovaCare, Inc. (RCAR)
USD 0.0
(-50.0%)
USD 0.0
(-50.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | - USD | -100.0% |
| 2021 | 5.4 Million USD | -44.1% |
| 2020 | 9.67 Million USD | 162.23% |
| 2019 | 3.69 Million USD | 83.78% |
| 2018 | 2 Million USD | -25.51% |
| 2017 | 2.69 Million USD | 42.02% |
| 2016 | 1.89 Million USD | 43.97% |
| 2015 | 1.31 Million USD | -38.14% |
| 2014 | 2.13 Million USD | 239.1% |
| 2013 | 628.54 Thousand USD | 139.97% |
| 2012 | 261.92 Thousand USD | -54.54% |
| 2011 | 576.2 Thousand USD | 78.6% |
| 2010 | 322.61 Thousand USD | 3.35% |
| 2009 | 312.16 Thousand USD | 9.86% |
| 2008 | 284.13 Thousand USD | 929.11% |
| 2007 | 27.61 Thousand USD | -66.7% |
| 2006 | 82.9 Thousand USD | 17.24% |
| 2005 | 70.71 Thousand USD | -59.97% |
| 2004 | 176.63 Thousand USD | -74.95% |
| 2003 | 705.03 Thousand USD | -27.39% |
| 2002 | 970.98 Thousand USD | 73.77% |
| 2001 | 558.77 Thousand USD | -42.25% |
| 2000 | 967.59 Thousand USD | 29.36% |
| 1999 | 747.99 Thousand USD | 102.51% |
| 1998 | 369.36 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q2 | - USD | 0.0% |
| 2023 Q1 | - USD | 0.0% |
| 2022 FY | - USD | -100.0% |
| 2022 Q3 | 1.87 Million USD | -11.81% |
| 2022 Q1 | 1.74 Million USD | -16.46% |
| 2022 Q4 | - USD | -100.0% |
| 2022 Q2 | 2.12 Million USD | 22.14% |
| 2021 Q4 | 2.08 Million USD | 22.68% |
| 2021 Q1 | 517.24 Thousand USD | -79.81% |
| 2021 Q3 | 1.7 Million USD | 53.84% |
| 2021 Q2 | 1.1 Million USD | 113.7% |
| 2021 FY | 5.4 Million USD | -44.1% |
| 2020 Q2 | 3.04 Million USD | 147.85% |
| 2020 Q4 | 2.56 Million USD | -9.9% |
| 2020 FY | 9.67 Million USD | 162.23% |
| 2020 Q3 | 2.84 Million USD | -6.62% |
| 2020 Q1 | 1.22 Million USD | -1.1% |
| 2019 Q3 | 1.2 Million USD | 86.59% |
| 2019 Q2 | 643.52 Thousand USD | 6.55% |
| 2019 Q4 | 1.24 Million USD | 3.44% |
| 2019 FY | 3.69 Million USD | 83.78% |
| 2019 Q1 | 603.97 Thousand USD | 9.26% |
| 2018 FY | 2 Million USD | -25.51% |
| 2018 Q3 | 432.49 Thousand USD | -3.77% |
| 2018 Q2 | 449.43 Thousand USD | -21.79% |
| 2018 Q4 | 552.78 Thousand USD | 27.81% |
| 2018 Q1 | 574.66 Thousand USD | -21.57% |
| 2017 Q4 | 732.7 Thousand USD | 27.48% |
| 2017 FY | 2.69 Million USD | 42.02% |
| 2017 Q3 | 574.74 Thousand USD | -42.88% |
| 2017 Q2 | 1 Million USD | 163.35% |
| 2017 Q1 | 382.1 Thousand USD | 19.35% |
| 2016 Q2 | 527.35 Thousand USD | -32.47% |
| 2016 Q4 | 320.14 Thousand USD | 18.92% |
| 2016 Q3 | 269.21 Thousand USD | -48.95% |
| 2016 Q1 | 780.89 Thousand USD | 44.52% |
| 2016 FY | 1.89 Million USD | 43.97% |
| 2015 Q3 | 297.03 Thousand USD | 37.56% |
| 2015 Q1 | 265.19 Thousand USD | 4.47% |
| 2015 Q2 | 215.93 Thousand USD | -18.58% |
| 2015 FY | 1.31 Million USD | -38.14% |
| 2015 Q4 | 540.34 Thousand USD | 81.92% |
| 2014 Q1 | 268.02 Thousand USD | -10.49% |
| 2014 FY | 2.13 Million USD | 239.1% |
| 2014 Q4 | 253.84 Thousand USD | -80.1% |
| 2014 Q3 | 1.27 Million USD | 282.35% |
| 2014 Q2 | 333.68 Thousand USD | 24.5% |
| 2013 Q3 | 184.86 Thousand USD | 121.77% |
| 2013 FY | 628.54 Thousand USD | 139.97% |
| 2013 Q2 | 83.35 Thousand USD | 18.45% |
| 2013 Q4 | 299.44 Thousand USD | 61.98% |
| 2013 Q1 | 70.37 Thousand USD | -2.73% |
| 2012 FY | 261.92 Thousand USD | -54.54% |
| 2012 Q2 | 69.28 Thousand USD | -14.62% |
| 2012 Q1 | 81.14 Thousand USD | -42.51% |
| 2012 Q3 | 39.15 Thousand USD | -43.48% |
| 2012 Q4 | 72.34 Thousand USD | 84.75% |
| 2011 Q2 | 133.35 Thousand USD | -10.72% |
| 2011 Q1 | 149.37 Thousand USD | 96.32% |
| 2011 Q3 | 152.32 Thousand USD | 14.22% |
| 2011 Q4 | 141.15 Thousand USD | -7.34% |
| 2011 FY | 576.2 Thousand USD | 78.6% |
| 2010 FY | 322.61 Thousand USD | 3.35% |
| 2010 Q4 | 76.08 Thousand USD | 2.63% |
| 2010 Q1 | 110.18 Thousand USD | 43.8% |
| 2010 Q2 | 62.21 Thousand USD | -43.53% |
| 2010 Q3 | 74.13 Thousand USD | 19.15% |
| 2009 Q4 | 76.62 Thousand USD | -9.3% |
| 2009 Q3 | 84.48 Thousand USD | 18.17% |
| 2009 Q2 | 71.49 Thousand USD | -10.15% |
| 2009 Q1 | 79.56 Thousand USD | -40.97% |
| 2009 FY | 312.16 Thousand USD | 9.86% |
| 2008 FY | 284.13 Thousand USD | 929.11% |
| 2008 Q1 | 14.8 Thousand USD | 110.79% |
| 2008 Q2 | 17.08 Thousand USD | 15.36% |
| 2008 Q4 | 134.8 Thousand USD | 14.5% |
| 2008 Q3 | 117.72 Thousand USD | 589.28% |
| 2007 Q2 | 9102.00 USD | 43.32% |
| 2007 Q4 | 7024.00 USD | 36.84% |
| 2007 Q3 | 5133.00 USD | -43.61% |
| 2007 FY | 27.61 Thousand USD | -66.7% |
| 2007 Q1 | 6351.00 USD | -75.33% |
| 2006 Q1 | 10.42 Thousand USD | -64.32% |
| 2006 FY | 82.9 Thousand USD | 17.24% |
| 2006 Q4 | 25.74 Thousand USD | 42.07% |
| 2006 Q3 | 18.11 Thousand USD | -36.69% |
| 2006 Q2 | 28.61 Thousand USD | 174.39% |
| 2005 Q1 | 6302.00 USD | 358.6% |
| 2005 Q2 | 10.88 Thousand USD | 72.77% |
| 2005 Q3 | 21.03 Thousand USD | 93.16% |
| 2005 Q4 | 29.23 Thousand USD | 39.0% |
| 2005 FY | 70.71 Thousand USD | -59.97% |
| 2004 Q1 | 82.01 Thousand USD | -41.38% |
| 2004 Q2 | 52.03 Thousand USD | -36.55% |
| 2004 FY | 176.63 Thousand USD | -74.95% |
| 2004 Q4 | -2437.00 USD | -105.41% |
| 2004 Q3 | 45.01 Thousand USD | -13.49% |
| 2003 Q1 | 206.11 Thousand USD | -68.03% |
| 2003 Q2 | 188.38 Thousand USD | -8.6% |
| 2003 FY | 705.03 Thousand USD | -27.39% |
| 2003 Q4 | 139.92 Thousand USD | -17.99% |
| 2003 Q3 | 170.61 Thousand USD | -9.43% |
| 2002 Q4 | 644.8 Thousand USD | 473.76% |
| 2002 Q2 | 107.08 Thousand USD | -21.52% |
| 2002 Q1 | 136.44 Thousand USD | -53.02% |
| 2002 FY | 970.98 Thousand USD | 73.77% |
| 2002 Q3 | 112.38 Thousand USD | 4.95% |
| 2001 Q4 | 290.41 Thousand USD | 325.38% |
| 2001 Q1 | 198.57 Thousand USD | -55.8% |
| 2001 FY | 558.77 Thousand USD | -42.25% |
| 2001 Q3 | 68.27 Thousand USD | -49.09% |
| 2001 Q2 | 134.1 Thousand USD | -32.47% |
| 2000 Q1 | 200.38 Thousand USD | 0.0% |
| 2000 Q2 | 180.77 Thousand USD | -9.79% |
| 2000 FY | 967.59 Thousand USD | 29.36% |
| 2000 Q3 | 137.22 Thousand USD | -24.09% |
| 2000 Q4 | 449.2 Thousand USD | 227.34% |
| 1999 FY | 747.99 Thousand USD | 102.51% |
| 1998 FY | 369.36 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | 100.0% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 100.0% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 100.0% |
| Nascent Biotech, Inc. | 2.22 Million USD | 100.0% |
| Rebus Holdings, Inc. | 664 Thousand USD | 100.0% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 100.0% |
| Qrons Inc. | 643.67 Thousand USD | 100.0% |
| Adynxx, Inc. | - USD | NaN% |
| Neon Bloom, Inc. | 389.56 Thousand USD | 100.0% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 100.0% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | 100.0% |
| Skye Bioscience, Inc. | 13.54 Million USD | 100.0% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 100.0% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 100.0% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | 100.0% |
| SQZ Biotechnologies Company | 85.61 Million USD | 100.0% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 100.0% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 100.0% |
| Mesoblast Limited | 5.9 Million USD | 100.0% |
| Marizyme, Inc. | 19.23 Million USD | 100.0% |
| Genus plc | 147.7 Million USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 100.0% |
| Pharming Group N.V. | 225.49 Million USD | 100.0% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 100.0% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 100.0% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 100.0% |
| ContraFect Corporation | 56.88 Million USD | 100.0% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | NaN% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 100.0% |
| IMV Inc. | 37.7 Million USD | 100.0% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 100.0% |
| MultiCell Technologies, Inc. | 567.42 USD | 100.0% |
| ONE Bio Corp. | 6.44 Million USD | 100.0% |
| Accustem Sciences Inc. | 3.74 Million USD | 100.0% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 100.0% |
| Arno Therapeutics, Inc. | - USD | NaN% |
| EV Biologics, Inc. | 531.96 Thousand USD | 100.0% |
| Q BioMed Inc. | 3.43 Million USD | 100.0% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 100.0% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 100.0% |
| Biomind Labs Inc. | 994.18 Thousand USD | 100.0% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 100.0% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 100.0% |
| TetraLogic Pharmaceuticals Corporation | - USD | NaN% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 100.0% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 100.0% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 100.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 100.0% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 100.0% |
| GB Sciences, Inc. | 1.42 Million USD | 100.0% |
| Alpha Cognition Inc. | 9.7 Million USD | 100.0% |
| HST Global, Inc. | 140.9 Thousand USD | 100.0% |
| CSL Limited | 3.44 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 100.0% |
| Halberd Corporation | 74.84 Thousand USD | 100.0% |
| Enzolytics Inc. | 2.17 Million USD | 100.0% |
| Agentix Corp. | 1.37 Million USD | 100.0% |
| Resverlogix Corp. | 12.71 Million USD | 100.0% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 100.0% |
| MetaStat, Inc. | - USD | NaN% |
| argenx SE | 1.53 Billion USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 100.0% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 100.0% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 100.0% |
| GeneThera, Inc. | - USD | NaN% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 100.0% |
| AVAX Technologies, Inc. | 7.31 Million USD | 100.0% |
| Zenith Capital Corp. | 8.94 Million USD | 100.0% |
| Genscript Biotech Corporation | 825.34 Million USD | 100.0% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | 100.0% |
| Anthera Pharmaceuticals, Inc. | - USD | NaN% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 100.0% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | 100.0% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 100.0% |
| Kadimastem Ltd | 2.41 Million USD | 100.0% |
| Helix BioMedix, Inc. | 1.97 Million USD | 100.0% |
| VitaSpring Biomedical Co. Ltd. | - USD | NaN% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 100.0% |
| BioStem Technologies, Inc. | 22.97 Million USD | 100.0% |
| Oncology Pharma Inc. | - USD | NaN% |
| Reve Technologies, Inc. | 181.48 Thousand USD | 100.0% |
| LadRx Corporation | 3.81 Million USD | 100.0% |
| Cell Source, Inc. | 4.32 Million USD | 100.0% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 100.0% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 100.0% |
| NovAccess Global Inc. | 2.46 Million USD | 100.0% |
| Affymax, Inc. | 39.38 Million USD | 100.0% |
| Itoco Inc. | 919.14 Thousand USD | 100.0% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 100.0% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 100.0% |
| Mobile Lads Corp. | 554.54 Thousand USD | 100.0% |
| CytoDyn Inc. | 18.05 Million USD | 100.0% |
| Claritas Pharmaceuticals, Inc. | - USD | NaN% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | 100.0% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | 100.0% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 100.0% |
| SYBLEU INC | 160.87 Thousand USD | 100.0% |
| Advanced Proteome Therapeutics Corporation | - USD | NaN% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 100.0% |
| International Stem Cell Corporation | 5.27 Million USD | 100.0% |
| Bioxytran, Inc. | 3.82 Million USD | 100.0% |
| GlobeImmune, Inc. | - USD | NaN% |
| Predictive Technology Group, Inc. | - USD | NaN% |
| ProText Mobility, Inc. | 52.64 Thousand USD | 100.0% |
| Cardax, Inc. | - USD | NaN% |
| VG Life Sciences Inc. | 20.34 Thousand USD | 100.0% |
| Kaleido Biosciences, Inc. | - USD | NaN% |
| Advaxis, Inc. | 36.26 Million USD | 100.0% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 100.0% |
| Regnum Corp. | 735.83 Thousand USD | 100.0% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 100.0% |
| Neutra Corp. | 243.82 Thousand USD | 100.0% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 100.0% |
| PureTech Health plc | 144.59 Million USD | 100.0% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 100.0% |
| IXICO plc | 4.7 Million USD | 100.0% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 100.0% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 100.0% |
| CSL Limited | 3.89 Billion USD | 100.0% |
| Cellectis S.A. | 97.32 Million USD | 100.0% |